The lifetime risk of RCC in SDHB mutation carriers is not well defined, but likely less than 10–15%; however, annual or biannual renal surveillance by MRI can be combined with screening for phaeochromocytoma/paraganglioma (which commences in older children). This evidence concerns the gene SDHB and renal cell adenocarcinoma.